ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning, and thank you for standing by. Welcome to the IMV Inc. first-quarter 2021 conference call. [Operator instructions] I would now like to hand the conference over to Pierre Labbé, chief financial officer.
Thank you. Please go ahead.
Pierre Labbe
Chief Financial Officer
Thank you, Takke. Good morning, everyone. My name is Pierre Labbé, CFO at IMV, and I m pleased to welcome you to our clinical and operational update and first-quarter financial results conference call. I m joined today by Fred Ors, our chief executive officer; and Andrew Hall, our chief business officer, who will be available for the question-and-answer period at the end of the call.
Operator
Good day, ladies and gentlemen and welcome to the Fate Therapeutics First Quarter 2021 Financial Results Conference Call. This call is being webcast live on the Investors section of Fate Therapeutics website at fatetherapeutics.com. [Operator Instructions]
I will now turn the call over to Scott Wolchko, President and CEO of Fate Therapeutics. Scott, you may begin.
Scott Wolchko
President And Chief Executive Officer
Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics first quarter 2021 financial results call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the Investors section of our website under Press Releases. In addition, our Form 10-Q for the quarter ended March 31, 2021 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for statements of his
Operator
Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I will now turn the call over to your host, Malin Deon with Jounce Therapeutics. Please go ahead.
Malin Deon
Manager, Investor Relations & Corporate Communications
Thank you, operator. Good morning, and welcome to the Jounce Therapeutics first quarter conference call. This morning we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors and Media section of our website at www.jouncetx.com.
Speaking on today s call will be our CEO and President, Dr. Rich Murray, who will review our pipeline progress, and key milestones, followed by our CSO, Dr. Dmitri Wiederschain, who will discuss our discovery efforts. Our CMO, Dr. Beth Trehu will then provide an update on our clinical activities, and lastly, our CFO, Kim Drapkin will review our first quarter financial resu